Comparison of supplemented Brucella agar and modified Clostridium difficile agar for antimicrobial susceptibility testing of Clostridium difficile

Annals of Laboratory Medicine

Volumn 34, Issue 6, 2014, Pages 439-445

  Kim, Gye Hyeong ^a,c   Kim, Jieun ^b   Pai, Hyunjoo ^b   Kang, Jung Oak ^a  

^a Hanyang University Guri Hospital   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

Antimicrobial susceptibility test; Clostridium difficile; Minimum inhibitory concentration; Susceptibility testing media

Indexed keywords

ANTIINFECTIVE AGENT;

CLOSTRIDIUM INFECTION; COMPARATIVE STUDY; DIARRHEA; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES;

ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84909981782     PISSN: 22343806     EISSN: 22343814     Source Type: Journal    
DOI: 10.3343/alm.2014.34.6.439     Document Type: Article

References (25)

1. Marler LM, Siders JA, Wolters LC, Pettigrew Y, Skitt BL, Allen SD. Comparison of five cultural procedures for isolation of Clostridium difficile from stools. J Clin Microbiol 1992;30:514-6.
2. Arroyo LG, Rousseau J, Willey BM, Low DE, Staempfli H, McGeer A, et al. Use of a selective enrichment broth to recover Clostridium difficile from stool swabs stored under different conditions. J Clin Microbiol 2005; 43:5341-3.
3. Kelly CP and LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008;359:1932-40.
4. Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005;173:1037-42.
5. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
6. Peláez T, Alcalá L, Alonso R, Rodríguez-Créixems M, García-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002;46:1647-50.
7. Huang H, Weintraub A, Fang H, Nord CE. Antimicrobial resistance in Clostridium difficile.Int J Antimicrob Agents 2009;34:516-22.
8. Clinical and Laboratory Standards Institute.Methods for animicrobialsusceptibilitytesting of anaerobic bacteria; Approved Standard. 7th ed. M11-A7. Wayne, PA: Clinical and Laboratory Standards Institute, 2007.
9. Bliss DZ, Johnson S, Clabots CR, Savik K, Gerding DN. Comparison of cycloserine-cefoxitin-fructose agar (CCFA) and taurocholate-CCFA for recovery of Clostridium difficile during surveillance of hospitalized patients. Diagn Microbiol Infect Dis 1997;29:1-4.
10. Aspinall ST and Hutchinson DN.New selective medium for isolating Clostridium difficile from faeces. J Clin Pathol 1992;45:812-4.
11. Erikstrup LT, Danielsen TK, Hall V, Olsen KE, Kristensen B, Kahlmeter G, et al. Antimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates. Clin Microbiol Infect 2012;18:E266-E72.
12. Bland JM and Altman DG. Statistics notes-Transforming data. Br Med J 1996;312:770.
13. Davies BI. The importance of the geometric mean MIC. J Antimicrob Chemother 1990;25:471-2.
14. Reynolds R, Hope R, Williams L: BSACWorking Parties on Resistance Surveillance. Survey, laboratory and statistical methods for the BSAC Resistance Surveillance Programmes. J Antimicrob Chemother 2008; 62(S2):ii15-28.
15. Kim H, Jeong SH, Roh KH, Hong SG, Kim JW, Shin MG, et al. Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. Korean J Lab Med 2010;30:491-7.
16. Huang H, Wu S, Wang M, Zhang Y, Fang H, Palmgren AC, et al. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes. Int J Antimicrob Agents 2009;33: 339-42.
17. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-9.
18. European Committee on Antimicrobial Susceptibility. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0. Basel: EUCAST, 2013.
19. Huang H, Weintraub A, Fang H, Wu S, Zhang Y, Nord CE. Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Anaerobe 2010;16:633-5.
20. Chen J, Jiang XY, Chen XQ, Chen Y. Effect of temperature on the metronidazole-BSA interaction: Multi-spectroscopic method. J Mol Struct 2008;876:121-6.
21. Zietsman S, Kilian G, Worthington M, Stubbs C. Formulation development and stability studies of aqueous metronidazole benzoate suspensions containing various suspending agents. Drug Dev Ind Pharm 2007; 33:191-7.
22. Wang DP and Yeh MK. Degradation kinetics of metronidazole in solution. J Pharm Sci 1993;82:95-8.
23. Kang JO, Han D, Choi TY. Evaluation of four methods for antimicrobial susceptibility testing of Helicobacter pylori in routine practice. Korean J Clin Microbiol 2005;8:82-9.
24. Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, Mastrantonio P, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008;62:1046-52.
25. Jiang ZD, DuPont HL, La Rocco M, Garey KW. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol 2010;63:355-8.